AC Immune (ACIU) Net Income towards Common Stockholders (2015 - 2026)
AC Immune's (ACIU) quarterly Net Income towards Common Stockholders came in at -$0.19 in Q1 2026, up 9.36% year-on-year from -$0.18 in Q1 2025, and up 99.98% on a QoQ basis from -$875.12 in Q4 2025.
AC Immune (ACIU) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$0.19 in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 9.36% year-over-year to -$0.19 in Q1 2026; TTM through Mar 2026 was -$875.76, a 50.43% decrease from a year earlier, with the FY2025 full-year figure at -$844.29, down 45.02% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$0.19, up from -$875.12 in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for ACIU reached as high as $0.07 in Q3 2024 and fell as low as -$19.9 million in Q2 2022.
- Historically, Net Income towards Common Stockholders has averaged -$2.3 million across 5 years, with a median of -$0.25 in 2025.
- Across the five-year window, Net Income towards Common Stockholders slumped 122905.79% in 2023 and surged 100.03% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$881.68 in 2022, then surged by 93.61% to -$56.37 in 2023, then plunged by 932.11% to -$581.78 in 2024, then tumbled by 50.42% to -$875.12 in 2025, then jumped by 99.98% to -$0.19 in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$0.19 in Q1 2026, -$875.12 in Q4 2025, and -$0.2 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | AC Immune | 230.22 Mn | 230.22 Mn | - | -0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.19 |
| Dec 31, 2025 | -875.12 |
| Sep 30, 2025 | -0.20 |
| Jun 30, 2025 | -0.25 |
| Mar 31, 2025 | -0.21 |
| Dec 31, 2024 | -581.78 |
| Sep 30, 2024 | 0.07 |
| Jun 30, 2024 | -0.25 |
| Mar 31, 2024 | -0.21 |
| Dec 31, 2023 | -56.37 |
| Sep 30, 2023 | -203.79 |
| Jun 30, 2023 | -0.22 |
| Mar 31, 2023 | -0.23 |
| Dec 31, 2022 | -881.68 |
| Sep 30, 2022 | -0.17 |
| Jun 30, 2022 | -19.91 Mn |
| Mar 31, 2022 | -19.57 Mn |
| Dec 31, 2021 | -1,051.20 |
| Sep 30, 2021 | -0.24 |
| Jun 30, 2021 | -19.26 Mn |